Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | CPA3 | P15088 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL12497328 | 1.00 | ALDH1A1 (0.96) | ALDH1A1CYP2D6CYP2C19CYP1A2TSHR | |
| SCHEMBL30793417 | 0.98 | ALDH1A1 (1.00) | ALDH1A1CYP2D6CYP2C19CYP1A2TSHR | |
| Bromide SCHEMBL28027685 | 0.96 | ALDH1A1 (0.88) | ALDH1A1CYP2D6CYP2C19CYP1A2TSHR | |
| Water SCHEMBL11301878 | 0.96 | ALDH1A1 (0.96) | ALDH1A1CYP2D6CYP2C19CYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL845765 | 0.96 | ALDH1A1 (0.96) | ALDH1A1CYP2D6CYP2C19CYP1A2TSHR | |
| Bromide SCHEMBL484781 | 0.88 | ALDH1A1 (0.74) | ALDH1A1CYP2D6CYP2C19CYP1A2TSHR | |
| Bromide SCHEMBL163452 | 0.86 | ALDH1A1 (0.71) | ALDH1A1CYP2D6CYP2C19CYP1A2TSHR | |
| SCHEMBL31204098 | 0.85 | ALDH1A1 (0.77) | ALDH1A1CYP2D6CYP2C19CYP1A2TSHR | |
| Bromide SCHEMBL3437057 | 0.84 | TSHR (0.69) | ALDH1A1CYP2D6CYP2C19CYP1A2TSHR | |
| Bromide SCHEMBL2854923 | 0.84 | TSHR (0.69) | ALDH1A1CYP2D6CYP2C19CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023159094-A2 | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2023137518-A1 | PLATINUM COMPLEXES | Western Sydney University (AU) | 2023-07-27 | — | — | WO | claimed |
| US-20220127238-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR BLOCKERS | HETERO LABS LIMITED (IN) | 2022-04-28 | — | — | US | claimed |
| CN-109456250-B | Thermal Activation Delayed Fluorescence (TADF) nano probe, preparation method thereof and application thereof in biological imaging | 哈尔滨医科大学 | 2022-03-04 | — | — | CN | claimed |
| CN-110256757-B | Quaternary phosphonium salt composite antibacterial EVA (ethylene-vinyl acetate) insole material and preparation method thereof | 广州大学 | 2021-12-28 | — | — | CN | claimed |
| CN-112410849-B | Preparation method and application of defect black phosphorus alkene carbon nanotube composite material | 肇庆市华师大光电产业研究院 | 2021-12-21 | — | — | CN | claimed |
| CN-113321747-A | Antibacterial component containing quaternary phosphonium salt modified locust bean gum | 广州市尚信净化工程有限公司 | 2021-08-31 | — | — | CN | claimed |
| CN-111990408-B | Nano antibacterial agent, preparation method and application thereof | 中国热带农业科学院农产品加工研究所 | 2021-06-01 | — | — | CN | claimed |
| CN-112410849-A | Preparation method and application of defect black phosphorus alkene carbon nanotube composite material | 肇庆市华师大光电产业研究院 | 2021-02-26 | — | — | CN | claimed |
| CN-111990408-A | Nano antibacterial agent, preparation method and application thereof | 中国热带农业科学院农产品加工研究所 | 2020-11-27 | — | — | CN | claimed |
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4739696-A1 | MITOCHONDRIA SPECIFIC TRANSCRIPTION INHIBITOR COMPOUNDS | Lunella Biotech, Inc. (CA) | 2026-05-13 | — | — | EP | disclosed |
| EP-4729508-A1 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4642784-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250320227-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2025-10-16 | — | — | US | disclosed |
| US-4228180-A | 7-Oxabicycloheptane and 7-oxabicycloheptene prostaglandin analogs | E. R. SQUIBB & SONS, INC. (US) | 1980-10-14 | — | — | US | disclosed |
| US-4165436-A | Trans-2,3-didehydro-9-deoxy-9-methylene-PGF compounds | THE UPJOHN COMPANY (US) | 1979-08-21 | — | — | US | disclosed |
| US-4052512-A | MENSTRUAL REGULATION | ONO PHARMACEUTICAL CO., LTD. (JA) | 1977-10-04 | — | — | US | disclosed |
| US-3987087-A | ANTI-ULCER, NASAL PATENCY, WOUND HEALING, LABOR INDUCEMENT | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3931296-A | Trans-Δ2 -prostaglandins | HAYASHI MASAKI | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127238-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR BLOCKERS | AGTR2, AGTR1, ADRB1 | ALDH1A1 991/4885CYP2D6 115/4885CYP2C19 72/4885 |
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | ALDH1A1 775/4885CYP2D6 246/4885CYP2C19 1312/4885 |
| US-20250320227-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | HCRTR1, HCRTR2, NPY1R | ALDH1A1 1670/4885CYP2D6 2176/4885CYP2C19 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.